StreetAlpha.app
Home › Stocks › GERN

Geron Corp (GERN)

Healthcare
$1.00
▲ +6.17%
LAST CLOSE · NOV 17

Geron is a biopharmaceutical company that sells RYTELO, a treatment for certain blood cancers. It last closed at $1.00 on Nov 17, up 6.17% on the day. The average 12-month price target from 2 analysts is $3.75 (+275.0% from the last close), with a high of $5.00 and a low of $2.50. In the past 30 days there were 1 dark pool print totaling $204K, the largest $204K.

AI Auto Pilots
Is GERN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$47.8M
EPS (diluted)
−$0.08
Valuation
Market cap
$644.2M
644.2M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$69.2M
At Sep 30
Debt
$120.4M
At Sep 30
Shareholder equity
$226.7M
Shares outstanding
644.2M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.4M$1.4MFY2021FY2022: $596K$596KFY2022FY2023: $237K$237KFY2023

From GERN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated GERN in the past 90 days, not enough for a consensus
Average 12-month target
$3.75
▲ 275.0% upside

Based on 2 analysts who set a price target on GERN in the past 90 days. The average target is $3.75, with a high of $5.00 and a low of $2.50, compared with the last close of $1.00.

Low $2.50Avg $3.75High $5.00
Blue marker: last close $1.00
Highest target$5.00
Average target$3.75
Lowest target$2.50
Latest rating changes
WedbushMaintained
Oct 29Buy$5
NeedhamMaintained
Oct 28Buy$2.50
DateFirmActionRatingPrice target
Oct 29WedbushMaintainedBuy$5
Oct 28NeedhamMaintainedBuy$2.50
Loading…

Technical Analysis

GERN · as of the Nov 17 close · updated after every close
Downtrend

The stock is 1% below its 20 day and 16% below its 50 day average. It is 40% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 45). The nearest support is the Pivot at $0.99, and the nearest resistance the 20 day average at $1.01.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.3%/day
Key levels
$2.0152 week high+101.0%
$1.40200 day average+40.0%
$1.31100 day average+31.0%
$1.1650 day average+16.0%
$1.09Swing high (Nov 5)+9.0%
$1.03Pivot R1+3.0%
$1.0120 day average+1.0%
$1.00Last close
$0.99Pivot−1.0%
$0.96Pivot S1−4.0%
$0.8452 week low−16.0%
$0.84Swing low (Oct 28)−16.0%
Indicators
RSI (14)44.70Middle of its rangeNeutral
MACD-0.06Above its signal lineBullish
Stochastic45.9Middle of its rangeNeutral
ADX (14)35.5Trending down
Williams %R-39.2Oversold below −80, overbought above −20Neutral
CCI (20)-25.0Oversold below −100, overbought above 100Neutral
Rate of change+7.5%Change over 10 sessionsBullish
ATR (14)$0.07Typical daily range, 7.3% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for GERN

What happened before

See how GERN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow GERN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How GERN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in GERN in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$204K
Largest print
$204K
Loading…

GERN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲112 buying vs 83 selling
  • ▼Held by funds -5.0 pts
  • ●Funds holding -1
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding260261−0.4%
In funds' top 1010–
Held by funds70.9%75.9%−5.0 pts
New / increased26 / 8634 / 96−13.8%
Reduced / sold out59 / 2460 / 30−7.8%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GERN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GERN is in one of them and how their past GERN trades turned out.

GERN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GERN in an article yet. Here's the latest on the wider market.

About Geron

Geron is a biopharmaceutical company based in Foster City, California, that develops treatments for blood cancers. Its main product is RYTELO, a telomerase inhibitor approved in the United States for adults with myelodysplastic syndrome who need frequent red blood cell transfusions. The company sells RYTELO to patients and health care providers in the U.S. and plans to make it available in select European Union markets through outside partners. It is also testing the drug in myelofibrosis, another blood cancer.

Headquarters
Foster City, CA
Founded
1990